You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,500,247


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,500,247 protect, and when does it expire?

Patent 10,500,247 protects GIAPREZA and is included in one NDA.

Summary for Patent: 10,500,247
Title:Method of treating low blood pressure
Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Inventor(s): Chawla; Lakhmir (McLean, VA)
Assignee: The George Washington University a Congressionally Chartered Not-for-Profit Corporation (Washington, DC)
Application Number:15/870,139
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,500,247: A Comprehensive Analysis

Introduction

Patent 10,500,247, like any other patent, is a complex document that outlines the scope, claims, and innovations of a specific invention. To analyze this patent, we need to delve into its various components, including the background, summary, detailed description, and claims. Here, we will provide a detailed analysis of the patent landscape and the specific elements of this patent.

Background of Patent 10,500,247

Before diving into the specifics, it is crucial to understand the context in which this patent was granted. The United States Patent and Trademark Office (USPTO) has stringent criteria for patentability, especially under the subject matter eligibility analysis outlined in 35 U.S.C. § 101[1].

Subject Matter Eligibility

The subject matter eligibility of a patent is a critical aspect, particularly for AI-related inventions. The 2024 Guidance Update by the USPTO emphasizes the importance of the two-pronged framework for determining patent eligibility. Prong One focuses on whether the claim elements recite abstract ideas, while Prong Two evaluates whether the claim elements integrate the abstract idea into a practical application[1].

Claims Analysis

Independent and Dependent Claims

Patent claims are the heart of any patent document. They define the scope of the invention and what is protected by the patent. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide more specific details[3].

Claim Language and Scope

The language used in the claims is crucial. Metrics such as independent claim length and independent claim count can provide insights into the scope of the patent. Narrower claims are often associated with a higher probability of grant and a shorter examination process[3].

Practical Application

For a patent to be eligible under Prong Two of the subject matter eligibility analysis, it must demonstrate that the claims are directed to a specific, concrete technological advancement or solution to a technical problem. This involves showing that the claimed invention improves the functioning of a computer or another technology or technical field[1].

Detailed Description

The detailed description section of the patent provides a comprehensive explanation of the invention, including drawings and diagrams. This section is essential for understanding how the invention works and its technical improvements.

Technical Improvements

To overcome section 101 rejections, the patent must show technical improvements. This can be demonstrated by technical explanations in the specification and by evaluating whether the claim accurately reflects these improvements[1].

Patent Landscape

Global Dossier and Public Search Facility

The USPTO's Global Dossier and Public Search Facility provide tools for analyzing the patent landscape. The Global Dossier allows users to see the patent family for a specific application, including related applications filed at participating IP Offices, and access to file histories and citation data[4].

Prior Art and Forward Citations

Analyzing prior art and forward citations can provide insights into the novelty and impact of the invention. Forward citations, in particular, indicate how often the patent is referenced by later patents, which can be a measure of its influence and scope[3].

Legal and Policy Considerations

False Advertising and Patent Marking

Patent holders must be cautious not to overstate the scope of their patent rights in advertising or marketing materials. False claims of patent protection can lead to false advertising claims under the Lanham Act, as seen in cases like Crocs, Inc. v. Effervescent, Inc.[5].

Small Claims Patent Court

There have been discussions and studies on the feasibility of a small claims patent court, which could impact how patent disputes are handled, especially for smaller entities. This could potentially affect the enforcement and defense of patents like 10,500,247[2].

Key Takeaways

  • Subject Matter Eligibility: The patent must pass the two-pronged test under 35 U.S.C. § 101, particularly demonstrating practical application under Prong Two.
  • Claims Analysis: Independent and dependent claims define the scope of the invention, with narrower claims often leading to a higher probability of grant.
  • Technical Improvements: The patent must show improvements in the functioning of a computer or another technology or technical field.
  • Patent Landscape: Tools like the Global Dossier and Public Search Facility are essential for analyzing related applications and prior art.
  • Legal Considerations: Avoid false advertising claims by accurately representing patent rights, and be aware of potential changes in patent dispute resolution mechanisms.

FAQs

Q: What is the significance of Prong Two in the subject matter eligibility analysis for AI inventions?

A: Prong Two is crucial as it requires demonstrating that the claims are directed to a specific, concrete technological advancement or solution to a technical problem, often by showing improvements in the functioning of a computer or another technology or technical field[1].

Q: How do independent and dependent claims differ in a patent?

A: Independent claims stand alone and broadly define the invention, while dependent claims build upon the independent claims and provide more specific details[3].

Q: What are the implications of false patent marking under the Lanham Act?

A: False patent marking can lead to false advertising claims under the Lanham Act, even without the intent to deceive the public. This can result in significant legal liabilities[5].

Q: How does the Global Dossier help in analyzing the patent landscape?

A: The Global Dossier provides access to file histories of related applications from participating IP Offices, allowing users to see the patent family, classification, and citation data for these applications[4].

Q: What is the potential impact of a small claims patent court on patent enforcement?

A: A small claims patent court could simplify and reduce the costs associated with patent disputes, particularly for smaller entities, potentially altering how patents are enforced and defended[2].

Sources

  1. Baker Botts, "The Importance of Prong Two of Step 2A for AI Inventions," September 2024.
  2. Administrative Conference of the United States, "U.S. Patent Small Claims Court," 2022.
  3. SSRN, "Patent Claims and Patent Scope," September 29, 2016.
  4. USPTO, "Search for patents," October 18, 2018.
  5. Fenwick & West LLP, "False Claims of Patent Protection Can Be False Advertising Under Lanham Act," October 11, 2024.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,500,247

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-003 Dec 23, 2021 RX Yes Yes 10,500,247 ⤷  Subscribe TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP ⤷  Subscribe
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-003 Dec 23, 2021 RX Yes Yes 10,500,247 ⤷  Subscribe TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION ⤷  Subscribe
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes 10,500,247 ⤷  Subscribe TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP ⤷  Subscribe
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes 10,500,247 ⤷  Subscribe TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.